



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

22 November 2016
EMA/HMPC/450587/2016
Committee on Herbal Medicinal Products (HMPC)

List of references supporting the assessment of *Piper methysticum* G. Forst., rhizoma

Draft

The European Medicines Agency acknowledges that copies of the underlying works used to produce this monograph were provided for research only with exclusion of any commercial purpose.

Anke J, Ramzan I. Pharmacokinetic and pharmacodynamic drug interactions with Kava (*Piper methysticum* Forst. f.). *J Ethnopharmacol* 2004, 93:153-60

Backhaus C, Kriegelstein J. Extract of kava (*Piper methysticum*) and its methysticin constituents protect brain tissue against ischemic damage in rodents. *Eur J Pharmacol* 1992, 215: 265–269

Barnes J, Anderson LA, Phillipson J D. Herbal Medicines 3rd ed. Pharmaceutical Press, London 2007, 389-403

Baum S, Hill R, Rommelspacher H. Effect of kava extract and individual kavapyrones on neurotransmitter levels in the accumbens of rats. *Prog Neuro-Psychopharmacol & Biol Psychiat* 1998, 22: 1105-20

Behl M, Nyska A, Chhabra RS, Travlos GS, Fomby LM, Sparrow BR et al. Liver toxicity and carcinogenicity in F344/N rats and B6C3F1 mice exposed to Kava Kava. *Food Chem Toxicol* 2011, 49:2820–29

Biber A, Noldner M, Schlegelmilch R. Development of a formulation of kava-kava extract through pharmacokinetic experiments in animals. *Naunyn Schmiedebergs Arch Pharmacol* 1992, R24 (Abstract 93)

Bilia AR, Gallon S, Vincieri FF. Kava-kava and anxiety: growing knowledge about the efficacy and safety. *Life Sci* 2002, 70: 2581 –2597

Blumenthal M, Busse WR, Goldberg A, Gruenwald J, et al., editors. The Complete German Commission E Monographs. American Botanical Council, Austin Texas 1990, 156–157

Bodkin R, Schneider S, Rekkerth D, Spillane L, Kamali M. Case Report Rhabdomyolysis associated with kava ingestion *American Journal of Emergency Medicine* 2012, 30: 635.e1–635.e3 Boonen G, Ferger B, Kuschinsky K, Häberlein H. In vivo Effects of the Kavapyrones (+)-Dihydromethysticin and(±)-Kavain



- on Dopamine, 3,4-Dihydroxyphenylacetic Acid, Serotonin and 5-Hydroxyindoleacetic Acid Levels in Striatal and Cortical Brain Regions. *Planta Med* 1998a, 64:507-10
- Boonen G, Hberlein H. Influence of Genuine Kavapyrone Enantiomers on the GABAA Binding Site. *Planta Med* 1998b, 64: 504-506
- Boerner RJ, Sommer H, Berger W, Kuhn U, Schmidt U, Mannel M- Kava-kava extract LI 150 is as effective as opipramol and buspirone in generalised anxiety disorder- an 8 week randomized, double-blind multi-centre clinical trial in 129 out-patients. *Phytomed* 2003, 10:38-49
- Brauer RB, Stangl M, Stewart JR, Pfab R, Becker K. Acute liver failure after administration of herbal tranquilizer kava-kava (*Piper methysticum*). *J Clin Psychiatry* 2003, 64: 216-218
- British Herbal Pharmacopoeia. 1st ed. British Herbal Medicine Association, Exeter 1990, 1: 162-3
- British Pharmaceutical Codex, The Pharmaceutical Press, London 1911, 557-8
- Brown AC, Onopa J, Holck P, Kaufusi P, Kabasawa D, Craig WJ, Dragull K, Levine AM, Baker JD. Traditional kava beverage consumption and liver function tests in a predominantly Tongan population in Hawaii. *Clin Toxicol* 2007, 45:549-56
- Bruneton J. Pharmacognosie, Phytochimie, Plantes medicinales, 3rd ed. Lavoisier, Paris 2005, 443-6
- Bujanda L, Palacios A, Silvarino R, Sanchez A, Munoz C. Kava-induced acute icteric hepatitis. *Gastroenterol Hepatol* 2002, 25:434-5
- Cagnacci A, Arangino S, Renzi A, Zanni AL, Malmusi S, Volpe A. Kava-Kava administration reduces anxiety in perimenopausal women. *Maturitas* 2003, 44:103-9
- Cairney S, Maruff P, Clough AR. The neurobehavioural effects of kava. *Australian and New Zealand J Psychiatry* 2002, 36: 657-62
- Capasso A, Sorrentino L. Pharmacological studies on the sedative and hypnotic effect of Kava kava and *Passiflora* extracts combination *Phytomed* 2005, 12:39-45
- Clayton NP, Yoshizawa K, Kissling GE, Burka LT, Chan P-C, Nyska A. Immunohistochemical analysis of expressions of hepatic cytochrome P450 in F344 rats following oral treatment with kava extract. *Exp Toxicol Pathol* 2007, 58: 223-36
- Clough AR, Bailie RS, Currie B. Liver function test abnormalities in users of aqueous kava extracts. *J Toxicol Clin Toxicol* 2003, 41:821-9
- Connor KM, Davidson JR. A placebo-controlled study of Kava kava in generalized anxiety disorder. *Int Clin Psychopharmacol* 2002, 17:185-8
- Connor KM, Payne V, Davidson JR. Kava in generalized anxiety disorder: three placebo-controlled trials. *Int Clin Psychopharmacol* 2006, 21:249-53
- Cropley M, Cave Z, Ellis J, Middleton RW. Effect of kava and valerian on human physiological and psychological responses to mental stress assessed under laboratory conditions. *Phytother Res*, 2002, 16: 23-7
- DAC 1998. Kava-Kava-Wurzelstock: K155-1-K155-6
- Davies LP, Drew CA, Duffield P, Johnston GAR, Jamieson DD. Kava pyrone and resin: Studies on GABAA, GABAB and benzodiazepine binding sites in rodent brain. *Pharmacol Toxicol* 1992, 71:120-126

- De Leo V, LaMarca A, Lanzetta D, Palazzi S, Torricelli M, Facchini C, Morgante G. Valutazione dell'associazione di estratto di Kava-Kava e terapia ormonale sostitutiva nel trattamento d'ansia in postmenopausa. *Minerva Ginecol* 2000, 52:263-7
- Di Silvestro RA, Zhang W, Di Silvestro DJ. Kava feeding in rats does not cause liver injury nor enhance galactosamine-induced hepatitis. *Food Chem Toxicol* 2007, 45: 1293–1300
- Dinh LD , Simmen U, Bueter BK , Bueter B, Lundstrom K, Schaffner W- Interaction of various *Piper methysticum* cultivars with CNS receptors *in vitro*. *Planta Med* 2001, 67: 306- 311
- Duffield AM, Jamieson DD, Lidgard RO, Duffield PH, Bourne DJ. Identification of some human urinary metabolites of the intoxicating beverage kava. *J Chromatogr A* 1989a, 475: 273–281
- Duffield PH, Jamieson DD, Duffield AM. Effect of aqueous and lipid-soluble extracts of kava on the conditioned avoidance response in rats. *Arch Int Pharmacodyn* 1989b, 301: 81–90
- Duffield PH, Jamieson DD. Development of tolerance to kava in mice. *Clin Exp Pharmacol Physiol* 1991, 18: 571–578
- Duke JA. Handbook of Medicinal Herbs 2nd ed. CRC Press, Boca Ratón 2002, 438
- Emser W, Bartylla K. Verbesserung der Schlafqualität. Zur Wirkung von Kava-Extrakt WS 1490 auf das Schlafmuster bei Gesunden TW *Neurol Psychiatr* 1991, 5: 636–642
- ESCOP Monographs 2nd ed. *Piperis methystici rhizoma* (kava-kava). European Scientific Cooperative on Phytotherapy, editor. Thieme, Stuttgart 2003, 365-382
- FDA, 2002. Consumer advisory: kava-containing dietary supplements may be associated with severe liver injury. US Food and Drug Administration. Available at: www.fda.gov/Food/ResourcesForYou/Consumers/ucm085482.html (Accessed on June 2016)
- Feltenstein MW, Lambdin C, Ganzera M, Dharmaratne RW, Nanayakkara D, Khan IA, Sufk K. Anxiolytic Properties of *Piper methysticum* extract samples and fractions in the chick social–separation–stress procedure. *Phytother Res* 2003, 17: 210- 216
- Fischer B, Hartwich C, editors. Hagers Handbuch der Pharmazeutischen Praxis. 5th ed. Vol 4. Springer-Verlag, Berlin 1919, 639
- Friese J, Gleitz J. Kavain, dihydrokavain, and dihydromethysticin non-competitively inhibit the specific binding of [3H]-batrachotoxinin-A 20- α -benzoate to receptor site 2 of voltage-gated Na⁺ channels. *Planta Med* 1998, 64:458-459
- Fu S, Korkmaz E, Braet F, Ngo Q, Ramzan I. Influence of kavain on hepatic ultrastructure. *World J Gastroenterol* 2008, 14: 541–546
- Fu S, Tattam BN, Duke CC, Ramzan I. High-performance liquid chromatography assays for desmethoxyyangonin, methysticin, kavain and their microsomal metabolites. *Biomed Chromatogr* 2009, 23: 81–91
- Fu S, Rowe A, Ramzan I. Kavalactone metabolism in the isolated perfused rat liver. *Phytother Res* 2012a, 26: 1813–1816
- Fu S, Rowe A, Ramzan I. Kavalactone metabolism in rat liver microsomes. *Phytother Res* 2012b, 26: 1057–1061
- Garner L, Klinger J. Some visual effects caused by the beverage kava. *J Ethnopharmacol* 1985, 13: 307-311

- Garrett K, Basmadjian G, Khan I, Schaneberg B, Seale TW. Extracts of kava (*Piper methysticum*) induce acute anxiolytic-like behavioral changes in mice. *Psychopharmacology* 2003, 170: 33–41
- Gastpar M, Klimm HD. Treatment of anxiety, tension and restlessness states with Kava special extract WS 1490 in general practice: a randomized placebo-controlled double-blind multicenter trial. *Phytomed* 2003, 10: 631-639
- Geier FP, Konstantinowicz T. Kava treatment in patients with anxiety. *Phytother Res* 2004, 18:297-300
- Gessner B, Cnota P. Untersuchung der Vigilanz nach Applikation von Kava-Kava-Extrakt, Diazepam oder Plazebo. *Z Phytother* 1994, 15: 30–37
- Gleitz J, Beile A, Peters T. (±)–Kavaine inhibits veratridine-activated voltage-dependent Na⁺-channels in synaptosomes prepared from rat cerebral cortex. *Neuropharmacol* 1995, 34: 1133 – 1138
- Gleitz J, Friese J, Belle A, Ameri A, Peters T. Anticonvulsive action of (±)–kavaine estimated from its properties on stimulated synaptosomes and Na⁺ channel receptor sites. *Eur J Pharmacol* 1996, 315: 89–97
- Gleitz J, Beile A, Wilkens P, Ameri A, Peters T. Antithrombotic action of the kava pyrone (+)–kavaine prepared from *Piper methysticum* on human platelets. *Planta Med* 1997, 63: 27–30
- Gow PJ, Connelly NJ, Hill RL, Crowley P, Angus PW. Fatal fulminant hepatic failure induced by a natural therapy containing kava. *Med J Aust* 2003, 178: 442-3
- Gruenwald J, Brendler T, Jaenicke C, editors. PDR for Herbal Medicines. 3rd ed. Thomson PDR, Montvale 2004, 482-89
- Hansel R, Woelk H, editors. Unerwünschte Wirkungen des Kavatrinkens/Toxicologie. In: Spektrum Kava-Kava, 2nd ed Aesopus Verlag, Basel 1995, 19-20
- Hänsel R, Keller K, Rimpler H, Schneider G, editors. Hagers Handbuch der Pharmazeutischen Praxis. 5th ed. Vol 6. Springer-Verlag, Berlin 1994, 201-12
- Hänsel R. Kava-Kava (*Piper methysticum* G. Forster) in der modernen Arzneimittelforschung. *Z Phytother* 1996, 17: 180–194
- Hänsel R. Characterization and physiological activity of some kava constituents. *Pacific Sci* 1968, 22:293-313
- Heinze HJ, Münthe TF, Steitz J, Matzke M. Pharmacopsychological effects of oxazepam and kava-extract in a visual search paradigm assessed with event-related potentials. *Pharmacopsychiat* 1994, 27: 224–230
- Holm E, Staedt U, Heep J, Kortsik C, Behne F, Kaske A, Mennicke I. Untersuchungen zum Wirkprofil von D,L-Kavaine. *Arzneim-Forsch/Drug Res* 1991, 41: 673 – 683
- Hsu SY, Lin MH, Lin LC, Chou CJ. Toxicologic studies of dihydro-5,6-dehydrokawain and 5,6-dehydrokawain. *Planta Med* 1994, 60: 88-90
- Jaggy H, Achenbach H. Cepharedione A from *Piper methysticum*. *Planta Med* 1992, 58: 111
- Jamieson DD, Duffield PH. The antinociceptive actions of kava components in mice. *Clin Exp Pharm Physiol* 1990, 17: 495–507
- Jhoo JW, Ang CY, Heinze TM, Deck J, Schnackenberg LK, Beger R D et al. Identification of C-glycoside flavonoids as potential mutagenic compounds in kava. *J Food Sci* 2007, 72: C120–125

- Johnson BM, Qiu SX, Zhang S, Zhang F, Burdette JE, Yu L et al. Identification of novel electrophilic metabolites of *Piper methysticum* Forst (kava). *Chem Res Toxicol* 2003, 16(6):733–740
- Johnson D, Frauendorf A, Stecker K, Stein U. Neurophysiologisches Wirkprofil und Vertäglichkeit von Kava-Extrakt WS 1490: eine Pilotstudie mit randomisierter Auswertung. *TW Neurologie Psychiatrie* 1991, 5:349-354
- Jussofie A, Schmitz A, Hiemke C. Kavapyrone enriched extract from *Piper methysticum* as a modulator of the GABA binding site in different regions of rat brain. *Psychopharmacol* 1994, 116: 469–474
- Keledjian J, Duffield PH, Jamieson DD, Lidgard RO, Duffield AM. Uptake into mouse brain of four compounds present in the psychoactive beverage kava. *J Pharm Sci* 1988, 77: 1003–1006
- Kretzschmar R, Teschendorf HJ, Ladous A, Ettehadieh D. On the sedative action of the kava rhizome. *Acta Pharmacol Toxicol* 1971, 29: 26
- Klohs MW, Keller F, Williams RE, Toekes MI, Cronheim GE. A chemical and pharmacological investigation of *Piper methysticum* Forst. *J Med Pharmaceut Chem* 1959, 1: 95–103
- Köppel C, Tenczer J. Mass spectral characterization of urinary metabolites of D,L-kavain. *J Chromatogr A* 1991, 562: 207–11
- Kretzschmar R, Meyer H. Über die antikonvulsive Wirksamkeit von Methysticin, einem Wirkstoff aus *Piper methysticum* Forst, in Kombination mit gebriuchlichen Antikonvulsiva. *Arch Int Pharmacodyn* 1965, 177: 267–8
- Lebot V, Merlin M, Lindstrom L. Kava The Pacific Elixir: The Definitive Guide to its Ethnobotany, History and Chemistry Yale University Press, New Haven 1992, 68-9
- Lebot V, Levesque J. Genetic control of kavalactone chemotypes in *Piper methysticum* cultivars. *Phytochem* 1996, 43: 397-403
- Lebot V, Legendre L. Comparison of kava (*Piper methysticum* Forst.) varieties by UV absorbance of acetonic extracts and high-performance thin-layer chromatography. *J Food Comp Anal* 2016, 48: 25–33
- Leulier M.M, Manceau P. *Precis de Matiere Medicale*, 5th ed. Vol 1. Librairie Maloine, Paris 1946, 615-6.
- Lehmann E, Klieser E, Klimke A, Krach H, Spatz R. The efficacy of kavain in patients suffering from anxiety. *Pharmacopsychiatry* 1989, 22: 258-262
- Lehmann E, Kinzler E, Friedemann J. Efficacy of a special Kava extract (*Piper methysticum*) in patients with states of anxiety, tension and excitedness of non-mental origin -A double-blind placebo-controlled study of four weeks treatment. *Phytomed* 1996, 3: 113-119
- Lehrl S. Clinical efficacy of kava extract WS 1490 in sleep disturbances associated with anxiety disorders. Results of a multicenter, randomized, placebo-controlled, double-blind clinical trial. *J Affect Disord* 2004, 78: 101-110
- Ligresti A, Villano R, Allarà M, Ujváry I, Di Marzo V. Kavalactones and the endocannabinoid system: The plant-derived yanonin is a novel CB1 receptor ligand. *Pharmacol Res* 2012, 66: 163–169
- Lim ST, Dragull K, Tang CS, Bittenbender HC, Efird JT, Nerurka PV. Effects of kava alkaloid, pipermethystine, and kavalactones on oxidative stress and cytochrome P450 in F-344 rats. *Toxicol Sci* 2007, 97: 214–221

Lindenberg D, Pitule-Schödel H. D,L-kavain in comparison with oxazepam in anxiety disorders. A double-blind study of clinical effectiveness [D,L-Kavain im Vergleich zu Oxazepam bei Angstzuständen. Doppelblindstudie zur Wirksamkeit]. *Fortschritte der Medizin* 1990, 108: 49-54

Lüde S, Török M, Dieterle S, Jäggi R, Büter KB, Krähenbühl S. Hepatocellular toxicity of kava leaf and root extracts. *Phytomedicine* 2008, 15: 120–131

Ma Y, Sachdeva K, Liu J, Ford M, Yang D, Khan IA, Chichester CO, Yan, B. Desmethoxyyangonin and dihydromethysticin are two major pharmacological kavalactones with marked activity on the induction of cytochrome P450A23. *Drug Metab Dispos* 2004, 32: 1317-1324

Madaus G. Lehrbuch der biologischen Heilmittel. Vol 1. Georg Thieme Verlag, Leipzig 1938, 2142-46

Magura EI, Kopanitsa MV, Gleitz J, Peters T, Krishtal OA. Kava extract ingredients, (+)-Methysticin and (±)-Kavain inhibit voltage-operated Na⁺ channels in rat CA1 hippocampal neurons. *Neurosci* 1997, 81: 345–51

Malsch U, Kieser M. Efficacy of kava-kava in the treatment of non psychotic anxiety, following pretreatment with benzodiazepines. *Psychopharmacol* 2001, 157: 277-283

Martindale. The Extra Pharmacopoeia. 29th ed. Pharmaceutical Press, London 2009, CD accessed.

Mathews JD, Riley MD, Fejo L, Munoz E, Milns NR, Gardner ID, Powers JR, Ganygulpa E, Gununuwawuy BJ. Effects of the heavy usage of kava on physical health: summary of a pilot survey in an aboriginal community. *Med J Aust* 1988, 148: 548-55

Mathews JM, Etheridge AS, Black SR. Inhibition of human cytochrome P450 activities by kava extract and kavalactones. *Drug Metab Dispos* 2002, 30: 1153–1157

Mathews JM, Etheridge AS, Valentine JL, Black SR, Coleman DP, Patel P et al. Pharmacokinetics and disposition of the kavalactone kawain: interaction with kava extract and kavalactones *in vivo* and *in vitro*. *Drug Metab Dispos* 2005, 33: 1555–1563

Matthias A, Blanchfield JT, Penman KG, Bone KM, Toth I, Lehmann RP. Permeability studies of Kavalactones using a Caco-2 cell monolayer model. *J Clin Pharm Ther* 2007, 32: 233–239

Meissner O, Häberlein H. HPLC analysis of flavokavins and kavapyrones from *Piper methysticum* Forst. *J Chromatogr B Analyt Technol Biomed Life Sci* 2005, 826: 46-49

Mittmann U, Schmidt M, Vrstyakova J. Akut -anxiolytische wirksamkeit von kava-spissum-spezialextrakt und benzodiazepinen als pramedikation bei chirurgischen eingriffen- ergebnisse einer randomisierten, referenzkontrollierten studie. *J Pharmakol U Ther* 2000, 4:99-108

Möller HJ, Heuberger L. Anxiolytic potency of D,L kavain. Results of a placebo-controlled, double-blind study [Anxiolytische Potenz von D,L-Kavain]. *Munchener Medizinische Wochenschrift* 1989, 131: 656–9

Möller HJ, Ulm K, Glöggler A. Kavain as an aid in the withdrawal of benzodiazepines (Therapy study) [Kavain als Hilfe beim Benzodiazepin-Entzug]. *Munchener Medizinische Wochenschrift* 1992, 134: 41–44

Münste TF, Heinze HJ, Matzke M, Steitz J. Effects of oxazepam and an extract of kava roots (*Piper methysticum*) on event related potentials in a word recognition task. *Neuropsychobiol* 1993, 27: 46–53

Narayanapillai S, Leitzman P, O'Sullivan G, Xing C. Flavokawains A and B in kava, not dihydromethysticin, potentiate acetaminophen-induced hepatotoxicity in C57BL/6 mice. *Chem Res Toxicol* 2014, 27: 1871–76

- Nerurkar PV, Dragull K, Tang C-S. *In vitro* toxicity of kava alkaloid, pipermethystine, in HepG2 cells compared to kavalactones. *Toxicol Sci* 2004, 79: 106–111
- Neuhaus W, Ghaemi Y, Schmidt T, Lehmann E- Zur Behandlung perioperativer Angste bei Mannakarzinomverdacht mit einem Phytotranquilizer. *Zentralbl Gynakol* 2000, 122: 561-565
- Norton SA, Ruze P. Kava dermopathy. *J Am Acad Dermatol* 1994, 31:89-97
- NTP (National Toxicology Program). Toxicology and carcinogenesis studies of kava kava extract (CAS No. 9000–38–8) in F344/N rats and B6C3F1 mice (gavage studies). National Toxicology Program Technical Report 2012, 571: 1–186
- Parmar VS, Jain S C, Bisht K, Jain R, Taneja P, Jha A, Tyagi OD, Prasad A K, Wengel J, Olsen CE, Boll PM. Phytochemistry of the genus *Piper*. *Phytochem* 1997, 46: 597–673
- Pittler MH, Ernst E. Efficacy of kava extract for treating anxiety: systematic review and meta-analysis. *J Clin Psychopharmacol* 2000; 20:84–9
- Pittler MH, Ernst E. Kava extract versus placebo for treating anxiety. Cochrane Database of Systematic Reviews 2003, Issue 1
- Pittler MH, Ernst E Kava extract versus placebo for treating anxiety (Review) Cochrane Database of Systematic Reviews 2010, Issue 6
- Rasmussen AK, Scheline RR, Solheim E, Hänsel R. Metabolism of some kava pyrones in the rat. *Xenobiotica* 1979, 9: 1–16
- Robinson V, Bergfeld WF, Belsito DV, Klaassen CD, Marks JG Jr, Shank RC et al. Cosmetic Ingredient Review Expert Panel. Final report on the safety assessment of *Piper methysticum* leaf/root/stem extract and *Piper methysticum* root extract. *Int J Toxicol* 2009, 28: 175S–188S
- Rowe A, Narlawar R, Groundwater PW, Ramzan I. Kavalactone pharmacophores for major cellular drug targets. *Mini Rev Med Chem* 2011, 11: 79 –83
- Ruze P. Kava-induced dermopathy: A niacin deficiency? *Lancet* 1990, 335: 1442 –45
- Russmann S, Barguil Y, Cabalion P, Kritsanida M, Duhet D, Lauterburg BH. Hepatic injury due to traditional aqueous extracts of kava root in New Caledonia. *Eur J Gastroenterol Hepatol* 2003, 15: 1033-36
- Saletu B, Grünberger J, Linzmayer L, Anderer P. EEG-brain mapping, psychometric and psychophysiological studies on central effects of kavain – a kava plant derivative. *Hum Pharmacol* 1989, 4: 169–190
- Sarris J, Scholey A, Schweitzer I, Bousman C, Laporte E, Murray G, Stough C. The acute effects of kava and oxazepam on anxiety, mood, neurocognition; and genetic correlates: a randomized, placebo-controlled, double-blind study. *Hum Psychopharmacol*. 2012, 27:262-9
- Scherer J. Kava-Kava extract in anxiety disorders: an outpatient observational study. *Adv. Ther* 1998, 15: 261-9
- Schmidt M. Is kava really hepatotoxic? An analysis of the known data on adverse effects of kava preparations on the liver. 2003, Available at: <http://www.uni-muenster.de/Chemie/PB/Kava/kavaframe.html> (Accessed Nov 3, 2011)

- Schmitz D, Zhang CL, Chatterjee SS, Heinemann U. Effects of methysticin on three different models of seizure like events studied in rat hippocampal and entorhinal cortex slices. *Naunyn Schmiedeberg's Arch Pharmacol* 1995, 351: 348–355
- Schulz V, Hansel R, Tyler VE. Rational phytotherapy: A physicians' guide to herbal medicine. 3th ed. Springer Verlag, New York 1999: 71-9
- Seitz U, Ameri A, Pelzer H, Gleitz J, Peters T. Relaxation of evoked contractile activity of isolated guinea-pig ileum by (±)-kavaine. *Planta Med* 1997, 63: 303–306
- Siegers CP, Honold E, Krall B, Meng G, Habs M. Ergebnisse der Anwendungsbeobachtung L 1090 mit Laitan Kapseln. *Ärztl. Forschung* 1992, 39:7-11
- Simeoni P, Lebot V. Identification of factors determining kavalactone content and chemotype in Kava (*Piper methysticum* Forst. F.) *Biochem System Ecol* 2002, 30: 413–424
- Singh YN. Kava: an overview. *J Ethnopharmacol* 1992, 37: 13–45
- Singh Y.N., Devkota A. Aqueous kava extracts do not affect liver function tests in rats. *Planta Med* 2003, 69: 496–499
- Sorrentino L., Capasso A., Schmidt M. Safety of ethanolic kava extract: Results of a study of chronic toxicity in rats, *Phytomed* 2006, 13: 542–549
- Spree MH, Croy HH. Antares - ein standardisiertes Kava-Kava-Präparat mit dem Spezialextrakt KW 1491. Therapeutische Ergebnisse und Verträglichkeit. *Der Kassenarzt* 1992, 17: 44-51
- Staedt U, Holm E, Heep J, Riesmüller S, Kortsik C, Steiner G. Studies on effects of D,L-Kawain- psychometry, EEG and Hamilton scale [Zum Wirkungsprofil von D,L-Kavain]. *Medizinische Welt* 1991, 42: 881–891
- Stickel F, Baumüller H-M, Seitz K, Vasilakis D, Seitz G, Seitz HK. et al. Hepatitis induced by Kava (*Piper methysticum* rhizoma). *J Hepatol* 2003, 39: 62–67
- Tang J, Dunlop RA, Rowe A, Rodgers KJ, Ramzan I. Kavalactones yangonin and methysticin induce apoptosis in human hepatocytes (HepG2) *in vitro*. *Phytother Res* 2010, 25: 417–423
- Tarbah F, Mahler H, Kardel B, Weinmann W, Hafner D, Daldrup T. Kinetics of kavain and its metabolites after oral application. *J Chromatogr B Analyt Technol Biomed Life Sci* 2003, 789: 115–130
- Teschke R, Lebot V. Proposal for a kava quality standardization code. *Food Chem Toxicol* 2011, 49: 2503–2516
- Teschke R, Fuchs J, Bahre R, Genthner A, Wolff A. Kava hepatotoxicity: comparative study of two structured quantitative methods for causality assessment. *J Clin Pharm Ther* 2010, 35: 545-563
- Teschke R, Schwarzenboeck A, Hennermann K-H. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. *Eur J Gastroenterol Hepatol* 2008, 20: 1182–1193
- Teschke R, Gaus W, Loew D. Kava extracts: safety and risks including rare hepatotoxicity. *Phytomed* 2003, 10: 440-446
- Teschke R, Genthner A, Wolff A. Kava hepatotoxicity: comparison of aqueous, ethanolic, acetonetic kava extracts and kava-herbs mixtures. *J Ethnopharmacol* 2009a, 123: 378-384
- Teschke R, Wolff A. Kava hepatotoxicity: regulatory data selection and causality assessment. *Digest Liver Dis* 2009b, 41: 891-901

Thompson R, Ruch W, Hasenhril RU. Enhanced cognitive performance and cheerful mood by standardized extracts of *Piper methysticum* (kava-kava). *Human Psychopharmacol* 2004, 19: 243–250

Trucksess M, Weaver C, Oles C, D'Ovidio K, Rader J. Determination of aflatoxins and ochratoxin A in ginseng and other botanical roots by immunoaffinity column cleanup and liquid chromatography with fluorescence detection. *J AOAC Int* 2006, 89: 624–630

Tzeng YM, Lee MJ. Neuroprotective properties of kavalactones. *Neural Regeneration Res* 2015, 10: 875-877

Uebelhack R, Franke L, Schewe H-J. Inhibition of platelet MAO-B by kava pyrone-enriched extract from *Piper methysticum* Fortser (Kava-Kava). *Pharmacopsychiatry* 1998, 31: 187–192

Unger M, Holzgrabe U, Jacobsen W, Cummins C, Benet LZ. Inhibition of cytochrome P450 3A4 by extracts and kavalactones of *Piper methysticum* (Kava-kava). *Planta Med* 2002, 68: 1055–1058

Volz HP, Kieser M. Kava-kava extract WS 1490 versus placebo in anxiety disorders-a randomized placebo-controlled 25-week outpatient trial. *Pharmacopsychiatry* 1997,30: 1-5

Walden J, Von Wegerer J, Winterz U, Berger M, Grunze H. Effects of Kawain and dihydromethysticin on field potential changes in the hippocampus. *Prog Neuro-Psychopharmacol. & Biol Psychiat* 1997, 21: 697-706

Wang J, Qu W, Bittenbender H C., Li QX. Kavalactone content and chemotype of kava beverages prepared from roots and rhizomes of *Isa* and *Mahakea* varieties and extraction efficiency of kavalactones using different solvents. *J Food Sci Technol* 2015, 52: 1164-1169

Warnecke G, Pfaender H, Gerster G, Gracza E. Wirksamkeit von Kava-Kava- Extrakt beim klimakterischen Syndrom. Eine Doppelblindstudie mit einem neuen Monopräparat. *Z Phytother* 1990,11: 81-6

Warnecke G. Psychosomatische Dysfunktionen im weiblichen Klimakterium. Klinische Wirksamkeit und Verträglichkeit von Kava-Extrakt WS 1490. *Fortschr Med* 1991, 109: 119-122

Weaver CM, Trucksess MW. Determination of aflatoxins in botanical roots by a modification of AOAC Official Method 991.31: single-laboratory validation. *J AOAC Int* 2010, 93(1): 184–189

Whittaker P, Clarke JJ, San RH, Betz JM, Seifried HE, de Jager LS et al. Evaluation of commercial kava extracts and kavalactone standards for mutagenicity and toxicity using the mammalian cell gene mutation assay in L5178Y mouse lymphoma cells. *Food Chem Toxicol* 2008, 46: 168–174

Whitton PA, Lau A, Salisbury A, Whitehouse J, Evans CS. Kava lactones and the kava-kava controversy *Phytochem* 2003, 64: 673-679

WHO Assessment of the risk of hepatotoxicity with kava products. World Health Organization Geneva, 2007

WHO monographs on selected medicinal plants. Vol. 2. Rhizoma *Piperis Methystici*. World Health Organisation. Geneva 2004, 231-245

Williamson EM. Potter's Herbal Cyclopaedia. CW Daniels, Saffron Walden, Essex 2003, 101-2

Witte S, Loew D, Gaus W. Meta-analysis of the efficacy of the acetonetic kava-kava extract WS1490 in patients with non-psychotic anxiety disorders. *Phytother Res*. 2005, 19: 183-8

- Woelk H, Kapoula O, Lehl S, Schröter K, Weinholz P. Behandlung von Angst Patienten. Doppelblindstudie: Kava-Spezialextrakt WS 1490 versus Benzodiazepine. *Z Allg Med* 1993, 69: 271-7
- Wu D, Yu L, Nair MG, DeWitt DL, Ramsewak RS. Cyclooxygenase enzyme inhibitory compounds with antioxidant activities from *Piper methysticum* (kava kava) roots. *Phytomed* 2002, 9: 41-47
- Yamazaki Y, Hashida H, Arita A, Hamaguchi K, Shimur F. High dose of commercial products of kava (*Piper methysticum*) markedly enhanced hepatic cytochrome P450 1A1 mRNA expression with liver enlargement in rats. *Food Chem Toxicol* 2008, 46: 3732–3738
- Zhang L, Rowe A, Braet F, Ramzan I. Macrophage depletion ameliorates kavalactone damage in the isolated perfused rat liver. *J Toxicol Sci* 2012, 37: 447–453
- Zhou P, Gross S, Liu J-H, Yu B-Y, Feng L-L, Nolta J, Sharma V, Worms D, Qiu S.X. Flavokawain B, the hepatotoxic constituent from kava root, induces GSH sensitive oxidative stress through modulation of IKK/NF-kappaB and MAPK signaling pathways. *FASEB J* 2010, 24: 4722–4732
- Zou L, Harkey MR, Henderson GL. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. *Life Sci* 2002, 71: 1579–1589
- Zou L, Harkey MR, Henderson GL. Synthesis, *in vitro* reactivity, and identification of 6-phenyl-3-hexen-2-one in human urine after kava-kava (*Piper methysticum*) ingestion. *Planta Med* 2005, 71: 142–146
- Zou L, Henderson GL, Harkey MR, Sakai Y, Li A. Effects of kava (kava-kava, 'awa, yaqona, *Piper methysticum*) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes. *Phytomed* 2004, 11: 285–294
- Xuan T, Fukuta M., Wei AC, Elzaawely AA, Khanh TD, Tawata S. Efficacy of extracting solvents to chemical components of kava (*Piper methysticum*) roots. *J Nat Med* 2008, 62 :188–194